NCT00862082 2013-08-23Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)Proacta, IncorporatedPhase 1/2 Terminated14 enrolled 15 charts